ABUSArbutus Biopharma Corporation
$4.20-5.2% 1Y
$4.20
$3.6752 weeks$5.20
Is the price fair?
What ABUS's price assumes
Arbutus Biopharma Corporation trades at 5.32× earnings against 19.8× for the median Biotechnology name, cheaper than its own group.
5.32
Trailing P/E · Biotechnology median 19.8 · cheaper than the typical name in its group
- Price / sales
- 5.21
Price / sales · as of 2026-Q2
- Price / book
- 3.66
Price / book · as of 2026-Q2
- EV / sales
- 4.70
EV / sales
Details›
- Price / bookas of 2026-Q2
- 3.66
- EV / EBITas of 2026-Q2
- 5.73
- EV / salesas of 2026-Q2
- 4.70
- Healthcare median P/E503 names
- 27.9
- Biotechnology median P/E242 names
- 19.8
- Market capitalisation197.8 million shares, counted Aug 10, 2026
- $831M
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Biotechnology
Ranks #18 of 194 by RyuScore